Time to hospital discharge · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in time to hospital discharge up to 26.10.2020, absolute effects for… compared with placebo (low certainty).
1 finding from 1 review
Mortality by day 60 · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (high certainty).
1 finding from 1 review
Resolution of symptoms · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
Azithromycin showed no clear difference in all initial symptoms resolved (asymptomatic) at day 14 compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in worsening of clinical status: participants with clinical… compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
Clinical improvement: discharged alive ( · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in improvement of clinical status: participants discharged alive at day… compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
All‐cause mortality at day 28 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
Admission to hospital or death within 28 days · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
Azithromycin showed no clear difference in admission to hospital or death within 28 days compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
All‐cause mortality assessed up to day 28 · individuals with moderate or severe COVID‐19
1 finding from 1 review
Adverse events within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Serious adverse events within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · individuals with moderate or severe COVID‐19
1 finding from 1 review
Improvement of clinical status: participants discharged alive up to day 28 without clinical deterioration or death · individuals with moderate or severe COVID‐19
1 finding from 1 review
All‐cause mortality up to day 28 · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Admission to hospital or death within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Time to alignment · Children or adolescents (aged 16 years old or under) receiving orthodontic treatment to prevent or correct crowded teeth
Copper nickel-titanium archwire showed no clear difference in time to alignment (days) compared with nickel-titanium archwire; GRADE not reported.
1 finding from 1 review
Trismus (dichotomous, 7th day) · People undergoing tooth extraction (21 of 23 trials: healthy patients undergoing impacted third molar extraction; 1 routine intra-alveolar…
It is very uncertain whether systemic antibiotic prophylaxis (any regimen; topical therapy… changes trismus (dichotomous, 7th day) compared with placebo (very low certainty).
1 finding from 1 review
Fever · People undergoing tooth extraction (21 of 23 trials: healthy patients undergoing impacted third molar extraction; 1 routine intra-alveolar…
It is very uncertain whether systemic antibiotic prophylaxis (any regimen; topical therapy… changes fever (6th-7th day) compared with placebo (very low certainty).
1 finding from 1 review
Clinical score (14 days) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether intralesional betamethasone changes clinical score (14 days) compared with intralesional triamcinolone acetonide (very low certainty).
1 finding from 1 review
Length of hospital stay · adults with acute stroke
Stroke ward showed no clear difference in length of stay (days) in a hospital or institution (Analysis 2.5) compared with general medical ward (low certainty).
1 finding from 1 review